Ixazomib

Introduction Overview

Generic Name

ixazomib

Brand Name

Ninlaro

Dosage Form

Oral capsule

Drug Class

Proteasome inhibitors

Pharmacokinetics

Absorption:
Ixazomib is absorbed orally with variable bioavailability influenced by food intake; it is recommended to take Ninlaro on an empty stomach, at least 1 hour before or 2 hours after meals, to optimize absorption. The drug achieves peak plasma concentrations typically within 1 to 2 hours post-dose. The oral capsules contain ixazomib citrate, which is rapidly converted to the active ixazomib in systemic circulation.

Distribution:
Ixazomib demonstrates extensive tissue distribution. It is moderately bound to plasma proteins (~99%) which suggests limited unbound active drug in plasma. The volume of distribution is large, indicating penetration into various tissues including the bone marrow, the primary site of multiple myeloma. Distribution is influenced by patient-specific factors such as hepatic and renal function.

Metabolism:
Ixazomib is metabolized primarily through enzymatic and non-enzymatic hydrolysis, with minor contributions from cytochrome P450 enzymes such as CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2D6, and CYP2C19. Metabolism produces inactive metabolites that are not pharmacologically active. The enzymatic pathways suggest potential interactions with other drugs affecting CYP enzymes.

Elimination:
Elimination of ixazomib occurs mainly through fecal excretion (approximately 62%) and renal excretion (~31%), primarily as metabolites. The drug has a terminal half-life of approximately 9.5 days, supporting once-weekly dosing. Clearance may be reduced in patients with hepatic or renal impairment, requiring dose adjustments. No accumulation is generally observed with the recommended dosing schedule.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 3 mg, 4 mg, and 5.5 mg strengths.

Dosages for Adults and Adolescents:
- Standard dosing for multiple myeloma involves 4 mg ixazomib orally once weekly on Days 1, 8, and 15 of a 28-day cycle.
- Therapy is continued until disease progression or unacceptable toxicity occurs.
- Used in combination with lenalidomide and dexamethasone for patients who have received at least one prior therapy.

Specific Patient Populations:
- Dose modifications are recommended for patients with hepatic or renal impairment.
- Not recommended for use in newly diagnosed patients outside clinical trials or for maintenance therapy.
- Both men and women of reproductive potential must use effective contraception during treatment and for at least 90 days post-last dose due to teratogenic risk.
- Capsules must be swallowed whole without crushing, chewing, or opening to avoid exposure to drug which can cause harm if in contact with skin or eyes.

Mechanism Of Action

Ixazomib, the active agent in Ninlaro, is a reversible inhibitor of the 20S proteasome, the proteolytic core of the 26S proteasome complex responsible for degrading ubiquitinated proteins within cells. Proteasomes play a critical role in regulating intracellular protein homeostasis, cell cycle progression, and apoptosis.

By selectively inhibiting the chymotrypsin-like activity of the 20S proteasome, ixazomib prevents degradation of ubiquitinated proteins, leading to accumulation of misfolded and regulatory proteins within malignant plasma cells. This disruption triggers cellular stress responses and apoptotic pathways, selectively inducing apoptosis in multiple myeloma cells that are highly dependent on proteasome function for survival.

At the molecular level, proteasome inhibition by ixazomib affects NF-kappaB signaling by stabilizing its inhibitor, IkB, thereby reducing transcription of growth and survival genes. This contributes to suppression of tumor cell proliferation and survival.

Clinically, ixazomib's oral bioavailability and once-weekly dosing offer convenient proteasome inhibition with efficacy comparable to parenteral proteasome inhibitors like bortezomib, but with a differentiated safety profile and cumulative toxicity considerations. Studies show that ixazomib combined with lenalidomide and dexamethasone significantly improves progression-free survival in relapsed/refractory multiple myeloma compared to standard regimens without ixazomib.

Pharmacological Actions

Selective, reversible inhibition of the 20S proteasome's chymotrypsin-like activity.
Induces apoptosis in malignant plasma cells by disrupting protein degradation and turnover.
Modulates critical signaling pathways such as NF-kappaB, leading to decreased tumor cell proliferation.
Enhances sensitivity of multiple myeloma cells to combination chemotherapy with lenalidomide and dexamethasone.
Reduces tumor burden by promoting cell cycle arrest and apoptotic pathways.
Exhibits oral bioavailability enabling convenient once-weekly dosing.
Demonstrates activity in multiple myeloma patients who have received prior therapies.
Potential immunomodulatory effects via increased expression of pro-apoptotic proteins.
Acts synergistically with other myeloma therapies, improving overall clinical outcomes.
Limits angiogenesis within the tumor microenvironment through proteasome inhibition.
Exerts minimal off-target toxicity due to its reversible binding and selective mechanism.

Therapeutic Or Clinical Uses

Treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Used in combination chemotherapy regimens with lenalidomide and dexamethasone.
Improves progression-free survival in relapsed/refractory multiple myeloma.
Option for patients unable to tolerate intravenous proteasome inhibitors.
Utilized for patients requiring convenient oral chemotherapy options.
Treatment in relapsed disease setting after prior proteasome inhibitors or immunomodulatory agent use.
Considered part of multi-agent regimens to maximize efficacy in multiple myeloma.
Not approved for maintenance therapy or initial frontline treatment outside clinical trials.
May be used in patients with compromised venous access due to oral administration format.
Serves as a backbone agent in combination for ongoing multiple myeloma clinical investigations.
Palliative therapy to reduce tumor load and associated myeloma-related complications.

Side Or Adverse Effects

Peripheral neuropathy causing numbness, tingling, pain, or burning sensations in extremities.
Thrombocytopenia leading to low blood platelet counts and increased bleeding risk.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and constipation.
Fatigue and asthenia commonly experienced during treatment.
Increased risk of infections due to neutropenia or immune suppression.
Rash and other skin reactions including severe dermatologic adverse events.
Fluid retention manifesting as edema in hands, feet, or rapid weight gain.
Hepatotoxicity presenting with elevated liver enzymes and jaundice in rare cases.
Herpes zoster reactivation necessitating antiviral prophylaxis in certain patients.
Low white blood cell counts increasing susceptibility to bacterial and viral infections.
Back pain which may be a symptom of disease or drug adverse effect.
Hypotension or dizziness especially related to concomitant dexamethasone use.
Gastrointestinal bleeding and mucositis in severe cases.
Allergic reactions including urticaria, facial swelling, or breathing difficulty requiring immediate care.

Precautions

Avoid use in patients with known hypersensitivity to ixazomib or capsule components.
Use with caution in patients with hepatic impairment; appropriate dose adjustments are necessary.
Monitor renal function frequently; dose reductions recommended for renal insufficiency or dialysis.
Contraception is critical for both men and women during and for 90 days after therapy due to teratogenic risk.
Do not breastfeed during treatment and for at least 90 days following last dose of Ninlaro.
Administer on an empty stomach to ensure consistent absorption.
Avoid concurrent administration of dexamethasone at the same time as Ninlaro to minimize gastrointestinal side effects.
Careful handling required to prevent exposure to capsule contents which are hazardous upon contact with skin or eyes.
Regular monitoring of blood counts, liver enzymes, and infection signs is necessary during therapy.
Advise patients to report symptoms suggesting venous thromboembolism or thrombotic microangiopathy immediately.
Provide antiviral prophylaxis in patients with history of varicella zoster infection to prevent reactivation.
Dose modifications should be made for hematological toxicities, non-hematological adverse events, or intolerable side effects.
Educate patients on recognizing signs of neuropathy and other adverse effects for prompt reporting.
Use caution with concomitant drugs metabolized via CYP450 pathways to avoid drug interactions.

Warnings

Not to be used during pregnancy or if a patient or their partner is pregnant due to severe risk of fetal harm.
Known risk of severe, life-threatening birth defects or fetal death associated with lenalidomide coadministration.
Risk of developing blood clots in small vessels (thrombotic microangiopathy) with potential organ damage.
Possibility of severe skin reactions including Stevens-Johnson syndrome; discontinue if severe rash occurs.
Potential for reactivation of herpes zoster; antiviral prophylaxis recommended.
Risk of severe hematological toxicities such as thrombocytopenia and neutropenia requiring dose adjustments.
Monitoring necessary to detect early signs of liver toxicity and fluid retention.
Avoid breastfeeding due to potential drug excretion in human milk and risk to infant.
Do not use for maintenance treatment or newly diagnosed multiple myeloma outside of clinical trials.
Avoid exposure to drug contents from broken capsules due to potential local irritation and toxicity.
Patients with past liver or kidney disease must be closely monitored during treatment.
Delayed hypersensitivity or allergic reactions can occur; seek immediate care if symptoms develop.
Not recommended to take multiple doses within short intervals; strict adherence to dosing schedule is essential.
Avoid combining with live vaccines due to immunosuppressive effects.

Contraindication

Hypersensitivity or allergy to ixazomib or any components of Ninlaro capsules.
Pregnancy due to high risk of fetal abnormalities and death.
Breastfeeding mothers during treatment and for 90 days post-treatment.
Concurrent use with lenalidomide in women who are pregnant or men with pregnant partners.
Severe hepatic impairment without appropriate dose modification based on clinical judgment.
Known active and uncontrolled infections until managed, due to immunosuppressive action.
Patients participating in maintenance therapy for multiple myeloma outside clinical trial settings.
Use in pediatric patients below the approved adult indication due to lack of safety and efficacy data.
Patients unable to swallow capsules whole or with conditions predisposing to impaired absorption.
Those with severe uncontrolled cardiovascular disease until stabilized prior to treatment.
Patients with severe concurrent illness that may confound assessment of adverse reactions.
Known intolerance or prior severe adverse response to proteasome inhibitors.
Pregnancy intended couples unwilling or unable to adhere to strict contraception guidance.

Drug Interactions

Potential interactions with CYP450 inhibitors or inducers that can alter ixazomib plasma levels.
Concomitant use with lenalidomide requiring strict pregnancy prevention measures due to teratogenic risk.
Dexamethasone should be administered separately from Ninlaro to optimize tolerability.
Immunosuppressive agents can heighten risk for infections when used concomitantly.
Antiviral agents often coadministered for prophylaxis against herpes zoster reactivation.
Drugs affecting platelet function or anticoagulants may increase bleeding risk in thrombocytopenic patients.
Avoid coadministration with strong CYP3A4 inducers which may reduce ixazomib efficacy.
Herbal supplements such as St. John’s Wort may alter metabolism and reduce effectiveness.
Use caution with nephrotoxic or hepatotoxic medications due to additive organ toxicity risks.
Live vaccines should be avoided as ixazomib suppresses immune responses.
Drugs altering gastric pH are unlikely to have significant effect due to capsule formulation but clinical monitoring is advised.
Co-administration with drugs causing peripheral neuropathy may exacerbate this toxicity.
Concurrent use with other myelosuppressive agents necessitates frequent blood monitoring.

Preparations Of The Drug

Oral capsules containing ixazomib citrate in 3 mg, 4 mg, and 5.5 mg strengths.
Each capsule is designed for once-weekly oral administration without food for optimized absorption.
Capsules should be stored in blister packs at room temperature, protected from moisture and heat.
Capsules must be swallowed whole with water; crushing, chewing, or opening capsules is contraindicated.
Packaging includes safety information regarding handling of capsules and disposal of broken or damaged capsules.
No intravenous or alternative injectable formulations currently available.
Packaged with detailed medication guides highlighting dosing schedules and safety warnings.
Special caution labels indicating teratogenicity and hazard of direct contact with capsule contents.
Supplemental patient information focusing on adherence, contraceptive measures, and infection risk.
Produced under strict quality controls to ensure consistent bioavailability and drug content.